Physician profile
Dinorah Nutis
NPI 1912934928
$20,940.79
in general payments reported to CMS, 2019-2025
54 companies · $3,047 in 2025
The $3,047 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,133 · 2020: $2,141 · 2021: $2,732 · 2022: $3,030 · 2023: $2,560 · 2024: $3,297 · 2025: $3,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,852 · Education: $52.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,851.65 |
| Education | $52.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,269.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $2,426.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $2,422.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,284.09 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $1,194.29 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $1,159.59 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $670.37 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $646.19 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $641.35 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $591.83 | 2019-2023 | |
| Abbott Laboratories | $525.78 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $525.45 | 2019-2022 | |
| Astellas Pharma US INC | $495.71 | 2019-2025 | Veozah |
| Pfizer INC. | $485.84 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $275.92 | 2023-2024 | Voquezna |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinorah Nutis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.